- Edwards Lifesciences is a leading global innovator in structural heart solutions, specializing in transcatheter heart valve replacement products and critical care monitoring systems, with a market cap of $47.04 billion as of April 2026.
- In Q4 2025, Edwards reported a 13.3% increase in sales to $1.57 billion, driven by a 12% growth in TAVR sales to $1.16 billion, and reaffirmed its 2026 revenue growth outlook of 8-10%.
- The company has established strong partnerships with healthcare providers and has seen significant adoption of its SAPIEN transcatheter aortic valve replacement products, which are crucial for treating patients with aortic stenosis.
- Edwards' ideal buyers are healthcare providers and hospitals focused on advanced cardiac care, as they seek innovative solutions to improve patient outcomes in structural heart diseases, particularly as the demand for TAVR procedures continues to rise.
Edwards Lifesciences operates with a diverse departmental structure comprising 19 distinct areas. The largest department is Information Technology, which employs 1,528 individuals, followed closely by Operations with 948 employees. Health Services also plays a significant role with a headcount of 663. This distribution indicates a strong emphasis on technology and operational efficiency, supporting the company's focus on innovation in medical products and equipment.
The company's workforce is geographically distributed across 439 locations, with a notable concentration in Irvine, California, which houses 2,279 employees. Other significant locations include Santa Ana with 282 employees and Draper, Utah, with 205. The large 'Other' category, accounting for 3,965 employees, suggests a widespread remote workforce or smaller offices, indicating a flexible operational model that supports diverse geographic engagement.
